Cardiothoracic & vascular anaesthesia

Perioperative Antithrombin Activity and Postoperative Outcomes in Adult Cardiac Surgery: A Prospective Cohort in Contemporary Plasma-Sparing Practice

J Cardiothorac Vasc AnesthPublished Prospective cohort study

Authors' conclusion

In cardiac surgery patients where plasma was avoided and no AT supplementation was used, low perioperative AT activity was associated with higher unadjusted complication rates but did not independently predict outcomes after accounting for patient and procedural factors.

Study context

Population
Adults (≥18 years) undergoing cardiac surgery with CPB at two academic centres using factor concentrate-based hemostatic algorithms without routine antithrombin (AT) supplementation
Participants
103 adults
Exposure
Lowest quintile vs higher quintiles of prebypass AT activity
Outcome
Co-primary: hospital and ICU LOS
Follow-up
To POD 28
Methodological detailsexploratory, observational, two-centre
  • Exploratory
  • Observational
  • Two-centre

Main finding

As reported in the abstract

Hospital and ICU LOS
  • Longer hospital stay in Q1 (unadjusted); prebypass AT status not an independent predictor in multivariable models

Observational data: associations, not effects.

Secondary outcomes

AKI and vasopressor/inotrope use beyond POD 1

Higher rates in Q1 (unadjusted); prebypass AT status not an independent predictor in multivariable models

Postbypass AT levels

Lower in Q1

Sensitivity analysis: postbypass AT threshold 63.7%

Similar results
  • Sensitivity analysis

Hemostatic therapy received

Plasma
2 (2%)
4F-PCC
23%
Fibrinogen concentrate
26%

Original publication

Perioperative Antithrombin Activity and Postoperative Outcomes in Adult Cardiac Surgery: A Prospective Cohort in Contemporary Plasma-Sparing Practice. J Cardiothorac Vasc Anesth. Published 24 September 2026. doi:10.1053/j.jvca.2026.08.157

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.